First Time Loading...

FibroGen Inc
NASDAQ:FGEN

Watchlist Manager
FibroGen Inc Logo
FibroGen Inc
NASDAQ:FGEN
Watchlist
Price: 1.14 USD -0.87% Market Closed
Updated: Apr 23, 2024

Intrinsic Value

FGEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. [ Read More ]

The intrinsic value of one FGEN stock under the Base Case scenario is 8.65 USD. Compared to the current market price of 1.14 USD, FibroGen Inc is Undervalued by 87%.

Key Points:
FGEN Intrinsic Value
Base Case
8.65 USD
Undervaluation 87%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
FibroGen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling FGEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
FibroGen Inc

Provide an overview of the primary business activities
of FibroGen Inc.

What unique competitive advantages
does FibroGen Inc hold over its rivals?

What risks and challenges
does FibroGen Inc face in the near future?

Has there been any significant insider trading activity
in FibroGen Inc recently?

Summarize the latest earnings call
of FibroGen Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for FibroGen Inc.

Provide P/S
for FibroGen Inc.

Provide P/E
for FibroGen Inc.

Provide P/OCF
for FibroGen Inc.

Provide P/FCFE
for FibroGen Inc.

Provide P/B
for FibroGen Inc.

Provide EV/S
for FibroGen Inc.

Provide EV/GP
for FibroGen Inc.

Provide EV/EBITDA
for FibroGen Inc.

Provide EV/EBIT
for FibroGen Inc.

Provide EV/OCF
for FibroGen Inc.

Provide EV/FCFF
for FibroGen Inc.

Provide EV/IC
for FibroGen Inc.

Show me price targets
for FibroGen Inc made by professional analysts.

What are the Revenue projections
for FibroGen Inc?

How accurate were the past Revenue estimates
for FibroGen Inc?

What are the Net Income projections
for FibroGen Inc?

How accurate were the past Net Income estimates
for FibroGen Inc?

What are the EPS projections
for FibroGen Inc?

How accurate were the past EPS estimates
for FibroGen Inc?

What are the EBIT projections
for FibroGen Inc?

How accurate were the past EBIT estimates
for FibroGen Inc?

Compare the revenue forecasts
for FibroGen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of FibroGen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of FibroGen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of FibroGen Inc compared to its peers.

Compare the P/E ratios
of FibroGen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing FibroGen Inc with its peers.

Analyze the financial leverage
of FibroGen Inc compared to its main competitors.

Show all profitability ratios
for FibroGen Inc.

Provide ROE
for FibroGen Inc.

Provide ROA
for FibroGen Inc.

Provide ROIC
for FibroGen Inc.

Provide ROCE
for FibroGen Inc.

Provide Gross Margin
for FibroGen Inc.

Provide Operating Margin
for FibroGen Inc.

Provide Net Margin
for FibroGen Inc.

Provide FCF Margin
for FibroGen Inc.

Show all solvency ratios
for FibroGen Inc.

Provide D/E Ratio
for FibroGen Inc.

Provide D/A Ratio
for FibroGen Inc.

Provide Interest Coverage Ratio
for FibroGen Inc.

Provide Altman Z-Score Ratio
for FibroGen Inc.

Provide Quick Ratio
for FibroGen Inc.

Provide Current Ratio
for FibroGen Inc.

Provide Cash Ratio
for FibroGen Inc.

What is the historical Revenue growth
over the last 5 years for FibroGen Inc?

What is the historical Net Income growth
over the last 5 years for FibroGen Inc?

What is the current Free Cash Flow
of FibroGen Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for FibroGen Inc.

Financials

Balance Sheet Decomposition
FibroGen Inc

Current Assets 331.6m
Cash & Short-Term Investments 235.6m
Receivables 41.1m
Other Current Assets 54.9m
Non-Current Assets 92m
Long-Term Investments 5.3m
PP&E 81.4m
Other Non-Current Assets 5.3m
Current Liabilities 217.7m
Accounts Payable 18m
Accrued Liabilities 186.9m
Other Current Liabilities 12.8m
Non-Current Liabilities 410m
Long-Term Debt 89.8m
Other Non-Current Liabilities 320.2m
Efficiency

Earnings Waterfall
FibroGen Inc

Revenue
147.8m USD
Cost of Revenue
-18.8m USD
Gross Profit
128.9m USD
Operating Expenses
-398.1m USD
Operating Income
-269.2m USD
Other Expenses
-15m USD
Net Income
-284.2m USD

Free Cash Flow Analysis
FibroGen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

FGEN Profitability Score
Profitability Due Diligence

FibroGen Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
ROE is Increasing
Positive Revenue Growth Forecast
30/100
Profitability
Score

FibroGen Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

FGEN Solvency Score
Solvency Due Diligence

FibroGen Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
38/100
Solvency
Score

FibroGen Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FGEN Price Targets Summary
FibroGen Inc

Wall Street analysts forecast FGEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FGEN is 1.79 USD with a low forecast of 1.52 USD and a high forecast of 2.1 USD.

Lowest
Price Target
1.52 USD
33% Upside
Average
Price Target
1.79 USD
57% Upside
Highest
Price Target
2.1 USD
84% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

FGEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

FGEN Price
FibroGen Inc

1M 1M
-57%
6M 6M
+125%
1Y 1Y
-93%
3Y 3Y
-95%
5Y 5Y
-98%
10Y 10Y
-95%
Annual Price Range
1.14
52w Low
0.38
52w High
19.19
Price Metrics
Average Annual Return -18.94%
Standard Deviation of Annual Returns 29.26%
Max Drawdown -99%
Shares Statistics
Market Capitalization 112.6m USD
Shares Outstanding 98 496 000
Percentage of Shares Shorted 6.91%

FGEN Return Decomposition
Main factors of price return

What is price return decomposition?

FGEN News

Last Important Events
FibroGen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
FibroGen Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

FibroGen Inc Logo
FibroGen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

112.6m USD

Dividend Yield

0%

Description

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 566 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. The firm is also enrolling patients in its two Phase III trials of pamrevlumab patients.

Contact

CALIFORNIA
San Francisco
409 Illinois St
+14159781200.0
http://www.fibrogen.com

IPO

2014-11-14

Employees

566

Officers

CEO & Director
Mr. Thane Wettig
Senior VP & CFO
Mr. Juan Graham
Senior Vice President of China Operations
Ms. Christine L. Chung
Founder
Dr. Barry A. Berkowitz Ph.D.
Chief Scientific Officer
Dr. John J. Hunter Ph.D.
Vice President of Corporate FP&A and Investor Relations
David DeLucia
Show More
Chief Legal Officer
Mr. Michael D. Lowenstein J.D., Ph.D.
Chief People Officer
Ms. Tricia Stewart
Chief Business Officer
Mr. Kirk A. Christoffersen MBA
Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing
Dr. Rahul Rajan Kaushik Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one FGEN stock?

The intrinsic value of one FGEN stock under the Base Case scenario is 8.65 USD.

Is FGEN stock undervalued or overvalued?

Compared to the current market price of 1.14 USD, FibroGen Inc is Undervalued by 87%.